Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 6/20 | 1.00 |
| ▸ | AHR | P35869 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | GOT1 | P17174 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.40 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1412900 | 0.82 | P2RX7 (0.69) | P2RX7AHRKMT2AMEN1GOT1 | |
| SCHEMBL1403853 | 0.80 | P2RX7 (0.67) | P2RX7AHRKMT2AMEN1CES1 | |
| SCHEMBL22290176 | 0.79 | P2RX7 (0.66) | P2RX7AHRKMT2AMEN1GAA | |
| SCHEMBL30674042 | 0.79 | P2RX7 (0.65) | P2RX7AHRKMT2AMEN1CES1 | |
| SCHEMBL4040893 | 0.78 | P2RX7 (0.65) | P2RX7AHRKMT2AMEN1GOT1 | |
| SCHEMBL21585657 | 0.78 | P2RX7 (0.64) | P2RX7AHRKMT2AMEN1GOT1 | |
| SCHEMBL1219748 | 0.78 | P2RX7 (0.64) | P2RX7AHRKMT2AMEN1MAPT | |
| Hydrochloric Acid SCHEMBL28798673 | 0.77 | P2RX7 (0.62) | P2RX7AHRKMT2AMEN1GOT1 | |
| SCHEMBL29374491 | 0.77 | — | — | |
| SCHEMBL667511 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107406412-A | TGF beta inhibitors | 里格尔药品股份有限公司 | 2017-11-28 | — | — | CN | claimed |
| EP-4559908-A1 | HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF | S2CBio Inc. (KR) | 2025-05-28 | — | — | EP | disclosed |
| EP-4426705-A1 | CYCLOHEPTA-THIENO-DIAZEPINE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE GABA A GAMMA1 RECEPTOR | F. Hoffmann-La Roche AG (CH) | 2024-09-11 | — | — | EP | disclosed |
| US-20240294543-A1 | CYCLOHEPTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN-LA ROCHE INC. (US) | 2024-09-05 | — | — | US | disclosed |
| US-20240190889-A1 | NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS | HOFFMANN-LA ROCHE INC. (US) | 2024-06-13 | — | — | US | disclosed |
| EP-4380940-A1 | NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | F. Hoffmann-La Roche AG (CH) | 2024-06-12 | — | — | EP | disclosed |
| EP-4126869-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAMS | HOFFMANN LA ROCHE (CH) | 2024-06-05 | — | — | EP | disclosed |
| CN-118019745-A | Cyclohepta-thieno-diazapine derivatives as positive allosteric modulators of the GABAA gamma 1 receptor | 豪夫迈·罗氏有限公司 | 2024-05-10 | — | — | CN | disclosed |
| CN-117881684-A | Novel cyclopenta-thieno-diazepine derivatives as GABAA gamma 1 PAM | 豪夫迈·罗氏有限公司 | 2024-04-12 | — | — | CN | disclosed |
| EP-4139310-B1 | BENZODIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | HOFFMANN LA ROCHE (CH) | 2024-03-27 | — | — | EP | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010125102-A1 | 5,6,7,8-TETRAHYDRO[1,2,4]TRIAZOLO[4,3-a]PYRAZINE DERIVATIVES AS P2X7 MODULATORS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | WO | disclosed |
| EP-2170337-A1 | NOVEL TRIAZOLOPYRIDAZINES | Abbott Laboratories (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090270402-A1 | Novel triazolopyridazines | ABBVIE INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009005675-A1 | NOVEL TRIAZOLOPYRIDAZINES | ABBOTT LABORATORIES (US) | 2009-01-08 | — | — | WO | disclosed |
| EP-1689406-A4 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC (US) | 2007-01-17 | — | — | EP | disclosed |
| EP-1689406-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2006-08-16 | — | — | EP | disclosed |
| WO-2005051906-A2 | HETEROCYCLIC INHIBITORS OF MEK AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2005-06-09 | — | — | WO | disclosed |
| CN-1114598-C | Aromatic compounds and pharmaceutical compositions containing them | ZENECA LTD (GB) | 2003-07-16 | — | — | CN | disclosed |
| CN-1229408-A | Dihydroindole derivatives useful as 5-HT-2C receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-09-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294543-A1 | CYCLOHEPTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 PAM | GABRA1, GRIN1, GABRA5 | P2RX7 505/4885AHR 1035/4885KMT2A 1507/4885 |
| US-20090270402-A1 | Novel triazolopyridazines | MAP3K5, MAP3K1, MAP3K2 | P2RX7 704/4885AHR 1915/4885KMT2A 2466/4885 |
| US-20240190889-A1 | NEW CYCLOPENTA-THIENO-DIAZEPINE DERIVATIVES AS GABA A GAMMA1 POSITIVE ALLOSTERIC MODULATORS | GABRA1, GABRA5, GABRB1 | P2RX7 301/4885AHR 2589/4885KMT2A 2860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.